A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

Abstract Background Current first-line standard of therapy for metastatic urothelial carcinoma is platinum-based combination chemotherapy. Pembrolizumab in phase III has demonstrated a promising overall response rate of 21.1% in patients with progression or recurrence after platinum-based chemothera...

Full description

Bibliographic Details
Main Authors: Nora Sundahl, Katrien De Wolf, Sylvie Rottey, Karel Decaestecker, Daan De Maeseneer, Annabel Meireson, Els Goetghebeur, Valérie Fonteyne, Sofie Verbeke, Pieter De Visschere, Dries Reynders, Mireille Van Gele, Lieve Brochez, Piet Ost
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Journal of Translational Medicine
Subjects:
Urothelial cell carcinoma
Radiotherapy
Immunotherapy
Pembrolizumab
Immunomonitoring
Randomized clinical trial
Online Access:http://link.springer.com/article/10.1186/s12967-017-1251-3

Internet

http://link.springer.com/article/10.1186/s12967-017-1251-3

Similar Items